Ichosia Biotechnology is developing a scalable method of mass-producing an enhanced red blood product, Erythrosyn, by leveraging proprietary genetic engineering techniques. Erythrosyn is created by genetically engineering human stem cells to transform into fully functioning red blood cell. By transitioning this natural erythropoietin process from the body into the laboratory, Erythrosyn is being designed to be producible on demand, universally compatible and more cost effective than donor blood.
View Top Employees from Ichosia BiotechnologyWebsite | http://www.ichosia.com |
Employees | 5 (5 on RocketReach) |
Founded | 2019 |
Address | 17 Briden St, Worcester, Massachusetts 01605, US |
Industry | Biotechnology, Discovery Tools (Healthcare), Other Healthcare Services |
Looking for a particular Ichosia Biotechnology employee's phone or email?
Meredith Westerlund is the COO of Ichosia Biotechnology.
5 people are employed at Ichosia Biotechnology.
Ichosia Biotechnology is based in Worcester, Massachusetts.